<DOC>
	<DOC>NCT00372853</DOC>
	<brief_summary>This study will determine the highest tolerable dose of CP-675,206 when given in combination with SU011248.</brief_summary>
	<brief_title>Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Histologically proven renal cell carcinoma with metastases Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1 Prior treatment with more than one systemic therapy for metastatic renal cell carcinoma History of or known brain metastases, spinal cord compression or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease on screening Computed Axial Tomography (CT) or Magnetic Resonance Imaging (MRI) scan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>